ZG005 Powder for Injection

BIOLOGICAL4 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Changsha Taihe Hospital

Conditions

Advanced Hepatocellular CarcinomaCervical CarcinomaSolid TumorSolid Tumors

Phase 1

A Study of ZG005 in Patients With Advanced Solid Tumors

RecruitingNCT06233292

Suzhou Zelgen Biopharmaceuticals Co.,LtdSolid Tumors

Start: 2022-06-17End: 2026-01-31Target: 484Updated: 2024-06-14

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

RecruitingNCT06239298

Suzhou Zelgen Biopharmaceuticals Co.,LtdSolid Tumor

Start: 2024-05-10End: 2026-05-31Target: 130Updated: 2024-06-14

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

RecruitingNCT06241235

Suzhou Zelgen Biopharmaceuticals Co.,LtdCervical Carcinoma

Start: 2024-03-27End: 2026-05-31Target: 48Updated: 2024-04-02

Unknown Phase

A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Not yet recruitingNCT06233994

Changsha Taihe HospitalAdvanced Hepatocellular Carcinoma

Start: 2024-01-31End: 2026-01-31Target: 30Updated: 2024-01-31

Related Papers

Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.

Journal of Clinical Oncology2025-05-28